SCHEMBL3974375

SCHEMBL3974375

O=C(O)c1cnc(Cl)c(Cl)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
TSHR P16473 2/20 0.39
HAVCR2 Q8TDQ0 1/20 0.39
GABRP O00591 2/20 0.38
GABRD O14764 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRB1 P18505 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRB2 P47870 2/20 0.38
GABRA4 P48169 2/20 0.38
GABRE P78334 2/20 0.38
GABRA6 Q16445 2/20 0.38
GABRG1 Q8N1C3 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7840908 0.83 LMNA (0.42) SMN1; SMN2LMNAKEAP1NFE2L2TSHR
SCHEMBL7850755 0.82 NAPRT (0.33) SMN1; SMN2LMNANAPRTALDH1A1
SCHEMBL391794 0.81 KEAP1 (0.44) SMN1; SMN2LMNAKEAP1NFE2L2TSHR
SCHEMBL29418647 0.81 KEAP1 (0.44) SMN1; SMN2LMNAKEAP1NFE2L2TSHR
SCHEMBL29781361 0.81 GABRP (0.43) SMN1; SMN2LMNAKEAP1NFE2L2TSHR
SCHEMBL3980791 0.81 GABRP (0.43) SMN1; SMN2LMNAKEAP1NFE2L2TSHR
SCHEMBL27407014 0.81 LMNA (0.41) SMN1; SMN2LMNAKEAP1NFE2L2TSHR
SCHEMBL27716685 0.81 HAVCR2 (0.50) SMN1; SMN2LMNAKEAP1NFE2L2TSHR
SCHEMBL3098275 0.81 GABRP (0.43) SMN1; SMN2LMNAKEAP1NFE2L2TSHR
SCHEMBL28204876 0.79 SMN1; SMN2 (0.40) SMN1; SMN2LMNAKEAP1NFE2L2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101575712-A Method for electrolytic synthesis of 4-amino-3,6-dichloropyridine-2-carboxylic acid HUNAN XIANGDA BIDE CHEMICAL CO (CN) 2009-11-11 CN claimed
CN-115551867-B Fused tricyclic compounds, pharmaceutical compositions and uses thereof 劲方医药科技(上海)有限公司 2024-02-20 CN disclosed
EP-2927214-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 EP disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 US disclosed
EP-2927214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-07 EP disclosed
EP-1673339-B1 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2013-07-03 EP disclosed
EP-1673339-B1 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2013-07-03 EP disclosed
CN-102960344-A Herbicidal composition for prevention and control of Mikania micrantha, its preparation method and application JIANGXI TIANREN ECOLOGY CO LTD 2013-03-13 CN disclosed
CN-101575712-A Method for electrolytic synthesis of 4-amino-3,6-dichloropyridine-2-carboxylic acid HUNAN XIANGDA BIDE CHEMICAL CO (CN) 2009-11-11 CN disclosed
EP-1673339-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2006-06-28 EP disclosed
US-20060030610-A1 Method of treating inflammatory diseases ARRAY BIOPHARMA INC. 2006-02-09 US disclosed
WO-2005023759-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2005-03-17 WO disclosed
US-20050054701-A1 Heterocyclic inhibitors of MEK and methods of use thereof ARRAY BIOPHARMA INC. 2005-03-10 US disclosed
EP-1248867-A1 SELECTIVE ELECTROCHEMICAL REDUCTION OF HALOGENATED 4-AMINOPICOLINIC ACIDS Dow AgroSciences LLC (US) 2002-10-16 EP disclosed
EP-1246802-A1 4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES Dow Agrosciences LLC (US) 2002-10-09 EP disclosed
WO-2001051684-A1 SELECTIVE ELECTROCHEMICAL REDUCTION OF HALOGENATED 4-AMINOPICOLINIC ACIDS DOW AGROSCIENCES, LLC (US) 2001-07-19 WO disclosed
WO-2001051468-A1 4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2001-07-19 WO disclosed
EP-0843666-A1 4-SUBSTITUTED 5-POLYCYCLYLPYRIMIDINE HERBICIDES DOWELANCO (US) 1998-05-27 EP disclosed
WO-1997037978-A1 4-SUBSTITUTED 5-POLYCYCLYLPYRIMIDINE HERBICIDES DOWELANCO (US) 1997-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR SMN1; SMN2 2509/4885LMNA 560/4885KEAP1 323/4885
US-20050054701-A1 Heterocyclic inhibitors of MEK and methods of use thereof NRAS, BRAF, RAF1 SMN1; SMN2 4003/4885LMNA 2380/4885KEAP1 734/4885
US-20060030610-A1 Method of treating inflammatory diseases TNF, MPO, FABP2 SMN1; SMN2 1978/4885LMNA 3593/4885KEAP1 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.